652 related articles for article (PubMed ID: 26546616)
1. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
3. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
Collier NJ; Ali FR; Lear JT
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
6. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
Chen L; Silapunt S; Migden MR
Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
8. Hedgehog Pathway Inhibition.
Sekulic A; Von Hoff D
Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
[TBL] [Abstract][Full Text] [Related]
9. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
10. Sonidegib for the treatment of advanced basal cell carcinoma.
Ramelyte E; Amann VC; Dummer R
Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
12. Sonidegib phosphate: new approval for basal cell carcinoma.
Tibes R
Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
[TBL] [Abstract][Full Text] [Related]
13. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
14. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
15. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
[TBL] [Abstract][Full Text] [Related]
17. Sonidegib: First Global Approval.
Burness CB
Drugs; 2015 Sep; 75(13):1559-66. PubMed ID: 26323341
[TBL] [Abstract][Full Text] [Related]
18. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
19. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
20. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
